Argus Says Abbott Laboratories Shares Favorably Valued Despite 'Heightened' M&A Risks

By: via Benzinga
Argus maintains its Buy rating and $55 price target on Abbott Laboratories (NYSE: ABT) after it posted better-than-expected ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.